Prevention strategies for sexually transmitted infections, HIV, and viral hepatitis in Europe

Basit Öğe Kaydı
dc.authoridBienkowski, Carlo/0000-0002-6488-4576
dc.authoridMitja, Oriol/0000-0003-3266-8868
dc.authoridInkaya, Ahmet Cagkan/0000-0001-7943-8715
dc.authorwosidMitja, Oriol/W-4181-2018
dc.contributor.authorGökengin, Deniz
dc.contributor.authorNoori, Teymur
dc.contributor.authorAlemany, Andrea
dc.contributor.authorBienkowski, Carlo
dc.contributor.authorLiegon, Geoffroy
dc.contributor.authorCarrillo, Jorge
dc.contributor.authorİnkaya, Ahmet Çağkan
dc.date.accessioned2024-08-25T18:51:46Z
dc.date.available2024-08-25T18:51:46Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractThe current prevention efforts for STIs, HIV and viral hepatitis in the WHO European Region, especially in the Central and Eastern subregions, are hindered by healthcare disparities, data gaps, and limited resources. In this comprehensive narrative review, we aim to highlight both achievements and persisting challenges while also exploring new developments that could significantly impact the prevention of these infections in the near future. While pre-exposure prophylaxis (PrEP) for HIV has been broadly approved and implemented in 38 out of 53 countries in the region, challenges remain, including cost, limited licensing, and incomplete adherence. We explore innovative approaches like on-demand PrEP, long-acting injectable cabotegravir, and intravaginal rings that have shown promising results, alongside the use of six-monthly lenacapavir, the outcomes of which are pending. Additionally, the potential of doxycycline post-exposure prophylaxis has been discussed, revealing efficacy in reducing chlamydia and syphilis risk, but effectiveness against gonorrhoea being contingent on tetracycline resistance rates, and the need of further data to determine potential resistance development in other bacteria and its impact on the gut microbiome. We examine successful vaccination campaigns against HBV and HPV, the ongoing development of vaccines for chlamydia, syphilis, herpesvirus, and gonorrhoea, and challenges in HIV vaccine research, including lines of research with significant potential like sequential immunization, T cell responses, and mRNA technology. This review underscores the research endeavors that pave the way for a more resilient and robust approach to combating STIs, HIV, and viral hepatitis in the region.en_US
dc.identifier.doi10.1016/j.lanepe.2023.100743
dc.identifier.issn2666-7762
dc.identifier.pmid37927439en_US
dc.identifier.urihttps://doi.org/10.1016/j.lanepe.2023.100743
dc.identifier.urihttps://hdl.handle.net/11454/102709
dc.identifier.volume34en_US
dc.identifier.wosWOS:001104422600001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofLancet Regional Health-Europeen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectPre-exposure prophylaxisen_US
dc.subjectPost-exposure prophylaxisen_US
dc.subjectPrevention vaccineen_US
dc.subjectHIVen_US
dc.subjectGonorrheaen_US
dc.subjectSyphilisen_US
dc.subjectChlamydiaen_US
dc.subjectHepatitis B or Cen_US
dc.subjectHPVen_US
dc.subjectsexually transmitted infectionsen_US
dc.subjectNeisseria-Gonorrhoeae Infectionen_US
dc.subjectPreexposure Prophylaxisen_US
dc.subjectPostexposure Prophylaxisen_US
dc.subjectHpv Vaccineen_US
dc.subjectDoxycycline Prophylaxisen_US
dc.subjectDouble-Blinden_US
dc.subjectHigh-Risken_US
dc.subjectMenen_US
dc.subjectSexen_US
dc.subjectEfficacyen_US
dc.titlePrevention strategies for sexually transmitted infections, HIV, and viral hepatitis in Europeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu